Shared core module

Positive Blood Cultures

The lab calls with a positive bottle. What needs to happen now, what can wait, and what information actually changes the plan?

Residents: essentials Fellows: advanced detail Core 30–45 min Edited November 10, 2026

Advanced fellow teaching is below

Complete the resident core or jump directly to the detailed teaching and reference sections.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

What you should be able to do

Resident core · 30–45 minutes with discussion

When the laboratory calls about a positive blood culture, the first questions are how ill the patient is, what grew, and where the samples came from. The answers help distinguish contamination from infection and identify a source that needs more than antibiotics.

  1. Decide whether a positive culture is likely to represent true bloodstream infection, contamination, or an unresolved result.
  2. Separate the likely portal of entry from possible endovascular or metastatic infection.
  3. Choose when follow-up blood cultures are useful and when they are probably unnecessary.
  4. Identify needed source control and determine which date should anchor treatment duration.
  5. Give the primary team a clear recommendation, including what could change it.

Interpreting the initial call

In an unstable patient, active empiric therapy and evaluation of the source proceed together. In a stable patient with a possible skin contaminant, reviewing the collection sites and devices may spare unnecessary treatment.

How sick?Is current therapy active, and can anything wait?
Is it real?What grew, from how many sets, and from which sites?
Where from?What is the likely source, and could another site have been seeded?
Repeat?Will another culture establish clearance or change the workup?
What needs fixing?Is there a line, device, obstruction, or collection that antibiotics will not solve?

For residents

  • Clinical stability determines how urgently empiric therapy is needed.
  • Aerobic and anaerobic bottles from one draw form a set. A second draw provides independent evidence.
  • A plausible source may explain entry into the blood, but it does not always explain the full extent of infection.
  • Follow-up cultures can establish clearance, test a suspected contaminant or point to an uncontrolled source.
  • The source and extent of infection influence both the need for a procedure and the length of treatment.

The organism changes the conversation

Species, the number of independently drawn sets that agree, collection sites, devices and the clinical course all affect interpretation. Two positive bottles from one venipuncture carry different weight from recovery of the same organism at two separate draws.

What the first result should trigger
ResultDefault interpretationImmediate questions
Act S. aureusEven one positive bottle usually represents bloodstream infection.Is therapy active? What do the exam, devices, follow-up cultures and echocardiography suggest about the source and extent? The 2026 consensus strongly encourages ID consultation to guide evaluation and treatment.1
Interpret S. lugdunensisThis coagulase-negative species can cause invasive infection. In one retrospective cohort with multiple sets collected, significant bacteremia was adjudicated in 12.1% of single-set positives versus 43.5% of multiple-set positives.Which independently drawn sets agree? Are there signs of endocarditis, an intravascular device or another focus? These findings guide repeat cultures and evaluation.10
Act YeastYeast in blood warrants prompt evaluation for fungemia. Candida is a leading concern; identification may reveal a different yeast.How ill is the patient? What therapy is likely to be active? Is there a catheter, abdominal leak or another focus?2, 9
Act Enterobacterales, Pseudomonas, other aerobic gram-negative rodsUsually true bacteremia, not skin contamination.Urinary, biliary, abdominal, pulmonary, vascular-catheter, wound, or device source; obstruction or undrained focus; active empiric therapy.
Interpret Enterococcus, viridans-group streptococciOften clinically significant, but context determines source and endovascular risk.Multiple sets, urinary or abdominal source, mucosal injury, valve/device history, persistence, unknown source, endocarditis features.
Interpret Coagulase-negative staphylococci, Corynebacterium, non-anthracis Bacillus, Cutibacterium, MicrococcusCommon contaminants when isolated from only one set in a low-risk host. They can be true pathogens, especially with intravascular or prosthetic material, immunocompromise, multiple concordant sets, or compatible illness.How many independently drawn sets? Same species? Peripheral or line draw? Hardware? Immunosuppression? Compatible syndrome? Need to repeat before committing to treatment?
One positive bottle. A common skin commensal growing in one of several independent sets is often a contaminant. If only one set was collected, that comparison is unavailable. Neither a laboratory contamination metric nor the number of positive bottles settles the diagnosis in a patient with a compatible illness or an implanted device.3

How much weight should we give time to positivity?

Time to positivity depends on organism burden, blood volume, prior therapy and the culture system. By itself, rapid or delayed growth cannot distinguish a pathogen from a contaminant.

A paired comparison answers a different question. If the same organism grows from catheter and peripheral samples drawn at the same time, with equal volumes and before antimicrobial therapy, growth from the catheter at least two hours earlier supports a catheter source.5

What can we safely do with a rapid panel result?

A rapid panel identifies only its listed organisms and resistance markers. A negative marker does not establish susceptibility, and in a mixed culture a detected gene may not identify which isolate carries it. Conventional culture and susceptibility testing resolve these questions. In a randomized trial, rapid testing reduced treatment of contaminants. Real-time stewardship feedback shortened time to appropriate de-escalation. The trial did not demonstrate a mortality difference.11 A meta-analysis found lower mortality associated with molecular rapid testing in studies with stewardship programs. The estimate from studies without stewardship was imprecise and did not reach statistical significance.8

Cases for discussion

For each case, pause before reading the discussion. Decide what you think the result means, what you need to do today, and what additional finding would change your mind.

Case 1: One set, one bottle, coagulase-negative staphylococcus

A stable patient admitted with a heart-failure exacerbation had one blood-culture set collected for a temperature of 37.9°C. One bottle grows coagulase-negative staphylococcus at 28 hours. There is no central line, prosthetic valve, cardiac device, vascular graft, or orthopedic hardware. Nothing else suggests an infection.

Before moving on

  • Would you call this bacteremia?
  • Would you continue vancomycin?
  • Do you need another culture?

Case discussion

Contamination is the most likely explanation if the isolate is a common skin commensal and the history and examination confirm the absence of hardware or a compatible illness. Only one set was collected, so there is no independent sample for comparison. In this setting, withholding or discontinuing vancomycin is reasonable.

New focal symptoms, an intravascular device or an uncertain history would make independently drawn peripheral sets useful. Sampling before additional antibiotics improves interpretation when the patient is stable enough.

The error here is allowing the word “positive” to settle the diagnosis. Contaminated cultures lead to unnecessary antibiotics, additional testing, adverse events, and longer hospitalization.3, 4

Case 2: One bottle with S. aureus and new back pain

A patient with no obvious source has one bottle positive for S. aureus. They are afebrile after antibiotics but mention new focal lumbar pain when you examine them.

What matters now?

  • Does one positive bottle change how seriously you take the result?
  • What studies need to be ordered today?
  • Does becoming afebrile lower the concern?

Case discussion

A single bottle growing S. aureus warrants evaluation for bacteremia. Active therapy, follow-up cultures and transthoracic echocardiography (TTE) help while examination and device history localize infection. Request early ID consultation. Use the TTE quality, follow-up cultures and endocarditis risk features to decide whether to proceed to TEE.1

Focal lumbar pain raises concern for vertebral or epidural infection even after fever resolves; MRI of the symptomatic spine can identify either. Follow-up cultures still positive at least 48 hours after collection of the index sample raise concern for an uncontrolled or additional focus.1

Case 3: E. coli bacteremia with an obstructed ureter

A patient with pyelonephritis and E. coli bacteremia undergoes ureteral decompression. They are hemodynamically stable and improving on active therapy. There is no prosthetic valve, endovascular graft, severe immunocompromise, or evidence of a deep focus.

Decisions for rounds

  • Do you need daily cultures until negative?
  • Why were both active antibiotics and decompression necessary?
  • When could oral treatment be reasonable?

Case discussion

Decompression relieved the obstruction; antibiotics alone could not restore urinary drainage. With adequate drainage and prompt clinical improvement on active therapy, repeat blood cultures are usually unnecessary.

For an adult with this controlled source and prompt response, seven total days of effective therapy is supported. The 2021 consensus counts from the first effective day, or from decompression if improvement began only then. Oral treatment is an option once the source is confirmed, the patient is improving and can absorb the drug, and susceptibility and systemic exposure are adequate. A susceptible fluoroquinolone or trimethoprim-sulfamethoxazole may meet these conditions. The 2025 IDSA complicated UTI guideline supports oral transition in selected improving, stable patients with effective oral options after relief of obstruction.6, 7, 13

Case 4: Yeast in blood after abdominal surgery

A patient develops shock after bowel surgery. An anastomotic leak is present, a central catheter is in place and one blood-culture bottle grows yeast.

What would you do tonight?

  • Could this be dismissed as contamination?
  • What has to happen besides starting an antifungal?
  • When does the treatment clock begin?

Case discussion

Treat yeast in blood in this patient as suspected candidemia and address the leak urgently while the laboratory identifies the organism. An echinocandin such as micafungin is a usual initial choice for suspected candidemia while the laboratory identifies the organism. Species and susceptibility may change that choice. Drainage or repair addresses the leak. Early catheter removal is favored when safe, particularly if the catheter is a likely source; during neutropenia the source and removal decision are more individualized.2, 9

For confirmed candidemia without an organ focus, the 2025 global guideline counts 14 days from the first of three consecutive days of negative blood cultures. Attributable symptoms must also have resolved; IDSA additionally requires recovery from neutropenia when present. Endocarditis, ocular disease or another deep focus requires a site-specific course.2, 9

Persistent candidemia, findings suggesting endocarditis such as a new murmur, underlying valve disease or a cardiac implant are reasons to evaluate with echocardiography in the 2025 global guideline.9

When should the cultures be repeated?

Follow-up cultures document clearance in S. aureus bacteremia and candidemia. With uncomplicated gram-negative bacteremia, a controlled source and prompt clinical improvement usually make repeat cultures unnecessary.

Organism-specific clearance strategy
SituationDefault strategyWhy
Adult S. aureus bacteremiaThe consensus suggests at least two sets 48 hours after the index sample was drawn, then one or two sets every 24–48 hours until clearance. Ongoing illness, a suspected deep focus or persistent growth may warrant closer sampling.The clearance date is the first negative draw after which S. aureus does not grow again. Persistence prompts a renewed search for the source.1
CandidemiaThe 2025 global guideline favors daily cultures until three consecutive days are negative. IDSA 2016 recommends daily or alternate-day sampling until clearance.Without organ involvement, the global guideline counts 14 days from the first persistently negative day. Symptoms and any neutropenia must also resolve before an uncomplicated course ends.2, 9
Uncomplicated gram-negative bacteremiaRepeat cultures are usually unnecessary when active therapy and source control lead to prompt improvement.Lack of improvement within 72 hours of effective therapy, limited source control or suspected endovascular infection warrants reassessment and repeat sampling.6
Possible contaminantNew peripheral sets can clarify whether an organism is present on independent draws, particularly with compatible illness, immunocompromise or a device.Sampling before new antibiotics, when safe, improves interpretation.
Bacteremia with deterioration, new focal symptoms or persistent feverRepeat cultures help assess ongoing infection.Inactive therapy, retained infected material and an undetected deep focus may explain failure to improve.
Why repeat? When catheter salvage is appropriate and attempted, continued growth in cultures drawn at 72 hours of active therapy is an indication for removal. A negative culture in an otherwise improving patient after relief of urinary obstruction may add little.5, 6

What are the antibiotics not going to fix?

On rounds, this is often the most important part of the discussion. Obstruction, an undrained collection, necrosis, a leak, or infected foreign material may require source control despite active antimicrobial therapy.

Remove

Is a catheter, cardiac device, vascular graft, or other hardware involved? If removal may be needed, identify who will make that decision and when.

Drain

An abscess, empyema or infected joint can sustain bacteremia. The location and accessibility of the collection determine how drainage can be achieved.

Debride

Is there necrotic tissue, an infected wound, devitalized bone, or an uncontrolled surgical focus? Antibiotics cannot restore perfusion or remove dead tissue.

Decompress or repair

Is there urinary or biliary obstruction, a leak, fistula, perforation, or another continuing anatomic problem?

Persistent S. aureus bacteremia. Growth in a follow-up sample drawn at least 48 hours after the index sample raises the risk of deep or metastatic infection. Persistent bacteremia despite active treatment prompts another examination for infected lines or devices, endocarditis and undrained foci.1

When the team thinks the line is the source

  • Were peripheral and catheter samples drawn together before antibiotics with equal blood volumes? Did the same organism grow from both?
  • Is the line still necessary, and can it be removed now?
  • Is there tunnel, pocket, exit-site, or septic-thrombus disease?
  • Is the organism one for which catheter retention carries a high failure risk?
  • If salvage is appropriate and attempted, are cultures drawn 72 hours after active therapy began still positive? Continued growth at that point is an indication for removal.

In confirmed catheter-related bloodstream infection, the 2009 IDSA guideline recommends removing short-term catheters for gram-negative bacilli, S. aureus, enterococci, fungi or mycobacteria. With a long-term catheter, severe sepsis, endocarditis, suppurative thrombophlebitis or infection due to S. aureus, P. aeruginosa, fungi or mycobacteria generally calls for prompt removal. The 72-hour checkpoint applies to an appropriate salvage trial. Alternative access and procedural risk can affect the removal plan.5

Answer the question the team actually has

A useful consult explains what the isolate means, which source is most likely and what finding would change that assessment. The same reasoning helps the next clinician interpret pending results.

A practical note structure

Positive blood cultures Blood cultures: [dates, number of sets, collection sites, identification, susceptibilities] Assessment: This is [true BSI / likely contamination / still uncertain]. The likely source is [ ] because [ ]. We remain concerned about [endovascular, prosthetic, or metastatic site] because [ ]. Plan today - Active therapy: [ ] - Repeat cultures: [what, when, and why] - Source control: [action, responsible service, expected timing] - Additional evaluation: [only tests likely to change management] Duration and follow-through - Duration anchor and anticipated stop date: [ ] - Pending results and who will review them: [ ] - Criteria for narrowing, oral transition, discharge, or reopening the workup: [ ]

Explaining the S. aureus case

“Even with one positive bottle, S. aureus is likely to be significant. Follow-up sets at 48 hours from the first draw help establish clearance; TTE assesses the valves. The new focal pain warrants spine MRI regardless of fever or culture clearance. Continued growth would raise concern for an uncontrolled focus.”

Before the patient leaves the hospital

  • A useful handoff identifies the treatment, route, monitoring, duration anchor and anticipated stop date.
  • Pending cultures and susceptibilities need an identified clinician who will act on the results.
  • The receiving team needs to know what was drained or removed and what material remains.
  • New focal pain, recurrent fever or instability after discharge warrants prompt reassessment.
  • When susceptibility, clinical response, absorption and adherence support an oral option, bacteremia alone does not require a central line.

Advanced fellow discussion begins here

The following questions explore when additional testing changes the interpretation of a positive culture.

Questions for fellows

  • Which uncertainty matters enough to change what you do today?
  • Are you applying an organism-specific approach or reflexively using the same workup for every bacteremia?
  • Is a prediction score helping with risk assessment, or are you asking it to exclude disease that it cannot reliably exclude?
  • What does the local rapid panel detect, and what can it miss?
  • If cultures remain positive, is the presumed source wrong, incompletely controlled, or not the whole story?

For fellows. In adult S. aureus bacteremia, the consensus suggests routine TTE. The panel suggests transesophageal echocardiography (TEE) even after a good-quality negative TTE if there is an intracardiac device, predisposing valve disease, positive follow-up cultures sampled at least 48 hours after the index culture, embolic events, or multiple noncontiguous foci. Community onset or injection drug use also merits consideration of TEE based on TTE quality, other risk features, clinical response and how a TEE result would change management. If signs and symptoms resolve and an adequate evaluation finds no deep or metastatic focus, the consensus suggests 14 days, including for selected increased-risk patients. The clock starts at clearance; removal of the focus later can serve as day one. Prolonged bacteremia, especially with an incomplete evaluation, may justify more than 14 days. A proven deep focus has its own treatment duration.1

For adults at increased risk for deep or metastatic infection with no source after appropriate initial evaluation, the consensus suggests whole-body imaging such as FDG PET/CT or a combination of studies directed at the likeliest sites.1

SABATO studied oral transition after 5–7 days of IV therapy in carefully selected low-risk adults. It excluded patients with signs of complicated bacteremia, nonremovable foreign devices, or severe comorbidity. Discuss oral transition with ID after clearance, source control, and evaluation for deep infection.14

For fellows. BALANCE found seven days noninferior to 14 for 90-day mortality among eligible hospitalized patients with bloodstream infection. The trial excluded severe immunosuppression, prosthetic heart valves or synthetic endovascular grafts, deep foci requiring prolonged therapy, S. aureus, S. lugdunensis, possible contaminants, unusual pathogens requiring prolonged therapy, and fungemia.7

When findings change the workup

Who needs an eye examination in candidemia?

New visual symptoms warrant prompt ophthalmologic assessment. Guidance differs for screening. IDSA 2016 recommends a dilated examination in the first week for nonneutropenic patients, and in the first week after neutrophil recovery for neutropenic patients. The American Academy of Ophthalmology advises against routine consultation for an asymptomatic positive culture alone. The 2025 global guideline favors fundoscopy with ocular symptoms, persistent candidemia, immunosuppression or inability to report symptoms.2, 9, 12

Calling it from the bottle count

“One bottle means contamination” and “two bottles mean true infection” are unreliable shortcuts. Start with the organism, independently collected sets, collection sites, host, devices, and syndrome.

Stopping once a plausible source is found

A positive urine culture may explain how bacteremia started. It does not make new back pain, an intracardiac device, persistent cultures, or embolic findings irrelevant.

Repeating cultures by habit

Follow-up cultures are essential in some infections and low yield in others. Know what question the next set is supposed to answer.

Changing antibiotics instead of controlling the source

A broader regimen does not drain an abscess, remove an infected line, decompress an obstruction, or debride necrotic tissue.

Overreading the rapid panel

An organism or resistance gene detected on a panel is not a complete phenotype. Know the local assay and wait for conventional results when they matter.

Choosing duration from memory

There is no single bacteremia duration. The answer depends on the organism, source, extent, source control, host, response, and the population actually studied.

Knowledge check

1. One of four bottles grows S. aureus. The patient looks well. Contaminant?

Answer

A single positive bottle usually represents true S. aureus bacteremia. A well appearance does not exclude endocarditis or another focus. Evaluate the source and request early ID consultation.

2. When should adult S. aureus follow-up cultures be obtained?

Answer

The 2026 IDSA/ESCMID consensus suggests at least two sets at 48 hours after sampling of the first positive culture, then one or two sets every 24 to 48 hours until negative. Ongoing illness, a deep or endovascular focus, or persistent growth may justify closer sampling.

3. Does every adult with S. aureus bacteremia need TTE?

Answer

The 2026 consensus suggests routine TTE for all adults with S. aureus bacteremia. TEE is risk-based after TTE, not automatically omitted because TTE is negative.

4. An improving patient has E. coli bacteremia from pyelonephritis after ureteral decompression. Repeat daily cultures?

Answer

Usually no, given effective drainage and a prompt response to active therapy. Limited source control, failure to improve or suspected endovascular infection changes that assessment.

5. One set grows Corynebacterium in a patient with a prosthetic valve. Ignore it?

Answer

No. It may still be contamination, but prosthetic material raises the consequence and probability of true infection. Reassess the syndrome and obtain properly collected repeat sets before dismissing it.

6. What does a catheter culture turning positive 2.5 hours before a simultaneous peripheral culture suggest?

Answer

If the same organism grew from catheter and peripheral samples drawn simultaneously before antibiotics with equal blood volumes, catheter growth at least two hours earlier supports a catheter source. Without those conditions, the interval is difficult to interpret.

7. Can the BALANCE trial justify 7 days for candidemia or S. aureus bacteremia?

Answer

No. The trial excluded fungemia, S. aureus, S. lugdunensis, deep foci requiring prolonged therapy, and other important high-risk groups.

8. What is the most useful one-sentence bacteremia recommendation?

Answer

One that states significance, source, next action, and contingency. Example: “This is true bacteremia from an obstructed urinary source; decompression is complete, repeat cultures are unnecessary if improvement continues, and oral treatment may be feasible if susceptibility, absorption and systemic exposure are adequate.”

Positive blood cultures: one-page rounds sheet

1. Validate

Organism. Independent sets and sites. Blood volume and collection quality. Host and devices. Compatible syndrome. Trajectory.

2. Stabilize

In suspected septic shock, active empiric treatment cannot wait for final identification or susceptibility.

3. Localize

Portal: urine, biliary/abdomen, lung, skin/wound, catheter. Extent: valve/device, thrombus, spine, joint, bone, abscess, embolic sites. Request early ID consultation for S. aureus bacteremia.

4. Clear selectively

S. aureus: ≥2 sets 48 h after index draw, then 1–2 sets every 24–48 h until clear. Candidemia: daily to 3 negative days (2025 global). Controlled, improving uncomplicated GN infection: usually no repeat.

5. Control

Is there an infected device, abscess, obstruction, leak or necrotic focus that requires a procedure? For catheter infection, check for prompt removal indications. The 72-hour culture checkpoint on active therapy applies to an appropriate salvage trial.

6. Set the clock

S. aureus: clearance, or later focus removal. Candidemia without organ disease: 14 days from sustained clearance; symptoms and any neutropenia must resolve.

7. Communicate

Significance + source + action + contingency. State what result or clinical change reopens the workup.

8. Handoff safely

Treatment and stop date; pending results and who will act; retained material, monitoring and symptoms needing reassessment.

Pitfalls: dismissing S. aureus or yeast on bottle count alone; repeating cultures without a question; relying on antibiotics for an obstructed or undrained focus; applying seven-day data to an excluded infection.

References and evidence notes

CONSENSUS reflects expert consensus informed by evidence review. GUIDELINE reflects a professional-society recommendation. RCT reflects randomized trial evidence. OBSERVATIONAL reflects nonrandomized data. Evidence labels matter because many bloodstream-infection practices remain consensus-based.

  1. CONSENSUS Liu C, Chambers HF, Vandenesch F, Kern WV, et al. IDSA/ESCMID 2026 Consensus Statements on Staphylococcus aureus Bacteremia: Risk Stratification, Diagnostic Evaluation, and Management of Adults and Children. Published and last updated September 9, 2026. IDSA consensus page.
  2. GUIDELINE Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by IDSA. Clin Infect Dis. 2016;62(4):e1-e50. Published online December 16, 2015. doi:10.1093/cid/civ933. IDSA guideline.
  3. LABORATORY REPORT Palavecino EL, Campodónico VL, She RC. Laboratory approaches to determining blood culture contamination rates: an ASM Laboratory Practices Subcommittee report. J Clin Microbiol. 2024;62(2):e01028-23. doi:10.1128/jcm.01028-23. Article.
  4. GUIDELINE / META-ANALYSIS Sautter RL, Parrott JS, Nachamkin I, et al. American Society for Microbiology evidence-based laboratory medicine practice guidelines to reduce blood culture contamination rates: a systematic review and meta-analysis. Clin Microbiol Rev. 2024;37(4). doi:10.1128/cmr.00087-24. Article.
  5. GUIDELINE Mermel LA, Allon M, Bouza E, et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by IDSA. Clin Infect Dis. 2009;49(1):1-45. doi:10.1086/599376. Full text. Archived guideline; IDSA lists an update in progress. Issuing organization and update status.
  6. CONSENSUS Heil EL, Bork JT, Abbo LM, et al. Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. Open Forum Infect Dis. 2021;8(10):ofab434. Published October 11, 2021. doi:10.1093/ofid/ofab434. Full text.
  7. RCT BALANCE Investigators for the Canadian Critical Care Trials Group, the Association of Medical Microbiology and Infectious Disease Canada Clinical Research Network, the Australian and New Zealand Intensive Care Society Clinical Trials Group, and the Australasian Society for Infectious Diseases Clinical Research Network. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med. Published online November 20, 2024; print 2025;392:1065-1078. doi:10.1056/NEJMoa2404991. PubMed. Protocol and exclusion criteria.
  8. SYSTEMATIC REVIEW Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis. Clin Infect Dis. 2017;64(1):15-23. doi:10.1093/cid/ciw649. PubMed.
  9. GUIDELINE Cornely OA, Sprute R, Bassetti M, et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2025;25(5):e280–e293. Guideline.
  10. COHORT Yogo A, Krishnan J, Lewin GR, Hojat LS, Ransom EM. Clinical implications of a single Staphylococcus lugdunensis-positive blood culture: true bacteremia vs. contamination. J Clin Microbiol. 2026;64(8):e00475-26. Study.
  11. RCT Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis. 2015;61(7):1071–1080. Trial.
  12. SOCIETY STATEMENT Breazzano MP, Bond JB, Bearelly S, et al. American Academy of Ophthalmology recommendations on screening for endogenous Candida endophthalmitis. Ophthalmology. 2022. Statement.
  13. GUIDELINE Trautner BW, et al. IDSA guideline update on complicated urinary tract infections. 2025. IDSA guideline.
  14. RCT Kaasch AJ, et al. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO). Lancet Infect Dis. 2024;24(5):523–534. Trial.
Initial approach Rounds sheet